Acquired pure red cell aplasia and T cell large granular lymphocytic leukaemia in patients with autoimmune polyglandular syndrome type 1

Jing Ruan, Xuan Wang, Xianyong Jiang and Miao Chen*

Abstract
Background: Pure red cell aplasia (PRCA) and large granular lymphocytic leukaemia (LGLL) are very rare complications of autoimmune polyendocrine syndrome type 1 (APS1). Here, we report a case of APS1 with PRCA and LGLL. Previous cases were reviewed, and possible mechanisms are discussed.

Case presentation: A 31-year-old female presented with anaemia and was diagnosed with PRCA in our centre. She also had hypoparathyroidism for 24 years, premature ovarian failure for 10 years, osteoporosis for 5 years, recurrent pneumonia with bronchiectasis for 4 years and chronic diarrhoea for 1 year. Boosted whole-exome analysis showed AIRE heterozygous mutations, confirming the diagnosis as APS1. LGLL was diagnosed during follow-up. The PRCA responded well to glucocorticoid treatment.

Conclusion: AIRE is causally related to the development of LGLL and consequent PRCA, which may be due to some immunological mechanisms.

Keywords: Pure red cell aplasia, Large granular lymphocytic leukaemia, Autoimmune polyendocrine syndrome type 1, AIRE gene mutation

Background
Pure red cell aplasia (PRCA) is a syndrome defined by anormocytic normochromic anaemia with severe reticulocytopenia and marked reduction or absence of erythroid precursors from the bone marrow [1]. Acquired PRCA is an autoimmune disorder involving autoantibodies or T cell-mediated inhibition of erythropoiesis. Secondary acquired PRCA may be associated with lymphoproliferative disorders, such as T cell large granular lymphocytic leukaemia (T-LGLL) [2], which is a monoclonal disorder of CD8-positive suppressor T cells. The clone of LGLL may target an erythroid antigen, resulting in erythroid hypoplasia and anaemia [2].

Here, we report a patient who presented with PRCA and T-LGLL and was ultimately diagnosed with autoimmune polyglandular syndrome type 1 (APS-1). APS-1 is a rare autosomal recessive or autosomal dominant disorder caused by mutations in the autoimmune regulator (AIRE) gene that help to reinforce immune tolerance by preventing the maturation of autoreactive T cells. The estimated prevalence is approximately 1:80,000 in most countries [3]. Clinical manifestations of APS-1 include mucocutaneous candidiasis, hypoparathyroidism, adrenal insufficiency and other autoimmune diseases [3–5]. PRCA and/or LGLL are very rare complications of APS-1. Previous
cases were reviewed, and possible immunological mechanisms are discussed.

**Case presentation**

A 31-year-old female presented with a pale face and tachycardia for 3 months. She was admitted in March 2018. Her past history included hypoparathyroidism for 24 years, premature ovarian failure for 10 years, osteoporosis for 5 years, recurrent pneumonia with bronchiectasis for 4 years and chronic diarrhoea for 1 year. Blood counts revealed severe anaemia (haemoglobin 50 g/L, mean corpuscular volume 99.5 fl) with normal white blood cells (WBCs) and platelets (WBCs 6.47 × 10⁹/L, neutrophils 2.45 × 10⁹/L, lymphocytes 3.6 × 10⁹/L, platelets 245 × 10⁹/L). The absolute reticulocyte count was 1.7 × 10⁹/L. No haemorrhage, haemolysis or nutritional anaemia was found. Intrinsic factor antibodies were positive (43.15 Au/ml). The glutamic acid decarboxylase antibody (GAD-Ab) level was 35 IU/ml. Anti-Ro 52 was positive (+++). A bone marrow smear showed normocellular marrow with a myeloid erythroid ratio of 68:1, which indicated PRCA (Fig. 1). The ASXL1 mutation (NM_015338:exon12: c.3946T: p.R1316C, variant allele fraction 51.28%) was detected, and her karyotype was normal. Flow cytometric analysis of the immunophenotype of the bone marrow showed that 96% of the lymphocytes were T cells, with an inversion ratio of CD4/CD8 cells. CD25, CD11c and CD56 were highly expressed, while CD16 was negative. Other secondary factors of PRCA were also evaluated. Virology testing, including for parvovirus B19, human immunodeficiency virus, Epstein-Barr virus and cytomegalovirus, yielded negative results. Rheumatoid factor, complement, and serum immunoglobulins were normal; antinuclear antibodies and antineutrophil cytoplasmic antibodies were negative. No solid tumour or lymphadenopathy was found on enhanced CT of the chest, abdomen or pelvis. Endocrine evaluation indicated adrenal insufficiency, with low adrenocorticotropic hormone levels. Along with her past medical history, autoimmune polyendocrine syndrome type 1, which can present with PRCA, was suspected. Boosted whole-exome analysis confirmed heterozygous mutations c.371C>T (p.Pro124Leu)(NM_000383.3) and c.623G>T (p.Gly208Val) (NM_000383.3) of the AIRE gene. Sanger’s sequencing showed that both mutations were inherited from her father, who had no symptoms, whereas the mother carried wild-type genes. In one report from the ClinVar database, c.371C>T is predicted to be likely pathogenic; c.623G>T is predicted to be damaging using PolyPhen and SIFT software.

The patient did not respond to cyclosporine A (CsA) at first due to malabsorption caused by diarrhoea, though methylprednisolone (32 mg qd) efficiently increased haemoglobin to normal levels in 1 month. However, during follow-up, we noticed persistent lymphocytosis after 2 months. The peripheral blood smear revealed 60% lymphocytes, and among them, 70% were large granular lymphocytes (Fig. 1). Immunophenotyping confirmed CD3, CD57 and TCRβ without CD56 expression (Fig. 2). T-cell receptor variable β-chain (TCRVβ) repertoire analysis showed that TCRβ14 accounted for 89.63% of the CD7dimCD5dim cells, which were monoclonal TCRβ cells. TCR gene rearrangement analysis revealed TCRγ. Thus, T large granular lymphocyte leukaemia (T-LGLL) was diagnosed.

During the reduction of glucocorticoids, cyclosporine A was added again but caused acute renal infarction (Cr 415 µmol/L), which was reversed after cessation of cyclosporine A. Sirolimus or tacrolimus combined with low-dose glucocorticoids only maintained 90 g/L haemoglobin after 6 months. Recently, her haemoglobin level
recovered to 110 g/L with methylprednisolone 8 mg/day, though lymphocytosis persisted (Fig. 3).

**Discussion and conclusions**

Autoimmune polyglandular syndrome type 1 (APS-1) is caused by mutations in the AIRE gene, which is located on chromosome 21 (21q22.3) and encodes the AIRE protein. Here, we report an APS-1 patient who harboured heterozygous mutations in AIRE, including c.371C>T (p.Pro124Leu) and c.623G>T (p.Gly208Val). These two mutations are novel and likely pathogenic according to the ClinVar database and function-prediction software. AIRE functions as a transcription factor and regulates the transcription of peripheral tissue antigens in thymic medullary epithelial cells. It plays a key role in shaping central and peripheral immunological tolerance by facilitating negative selection of autoreactive T cells in the thymus and inducing a specific subset of regulatory T cells [6, 7].

In the absence of AIRE, autoimmunity develops from two failed tolerance mechanisms targeting more than one endocrine organ and a nonendocrine organ. APS-1 can be diagnosed clinically based on the appearance of at least two of the three conditions: candidiasis, hypoparathyroidism and adrenocortical failure [4, 5]. In this patient, hypoparathyroidism was the first manifestation of APS-1 and occurred at the age of seven years old. She also had adrenal insufficiency and other endocrinological symptoms, such as premature ovarian and osteoporosis. Mucocutaneous candidiasis was not observed. Moreover,
she had chronic diarrhoea and recurrent pneumonia with bronchiectasis.

Haematological abnormalities have also been identified in APS-1. In the largest cohort study of APS-1, consisting of 112 patients in Russia, pernicious anaemia was seen in 8% (10/112) [8]. Pernicious anaemia is the most common cause of anaemia as a result of autoimmune gastritis with vitamin B12 deficiency [3]. In the above study, PRCA was only found in 1% of the patients [8], with coexistence with large granular lymphocyte leukaemia in some. Autoimmune haemolytic anaemia is very rare [9, 10]. Eight cases of PRCA associated with APS-1 have been reported [11–17], of which only four had coexisting LGLL [15–17]. All four patients were female, and their first manifestations of APS-1 were during childhood. PRCA and T-LGLL were diagnosed simultaneously. Three patients were in their 20 s, and one was 46 years old. In the current case, APS-1 preceded PRCA and T-LGLL by 24 years. This may not be a coincidence, as APS-1, PRCA and T-LGLL are all rare diseases, and PRCA and LGLL can even develop in siblings with the same AIRE mutation [18]. To date, some mechanisms for patients diagnosed with LGLL with PRCA have been explored [19]. Regarding molecular mechanisms, STAT3 mutations have been found in some PRCA patients with LGLL [20], though it remains uncertain whether STAT3-mutated T cells have an inhibitory effect on erythroid cell production. Furthermore, STAT5b mutations have essential roles in the survival and proliferation of haematopoietic cells. Nonetheless, the present patient did not carry STAT3 or STAT5b mutations. Regarding the immune mechanism, Handgretinger et al. [21] reported that in a patient with γδT-LGLL-associated PRCA, γδT-LGLs inhibited erythroid precursors by KIRs. It is possible that autoimmunity of APS-1 may predispose an individual to the development of clonal proliferation of LGLs. The T-LGLL clone might recognize a self-antigen and expand due to AIRE regulatory failure and lack of deletion of that T cell clone. The LGLL clone targets an erythroid antigen, resulting in PRCA.

Treatment responses to glucocorticoid and immunosuppressive drugs such as cyclophosphamide [12, 15] or mycophenolate-mofetil [13] vary among cases. In our case, glucocorticoids resulted in remission of PRCA, though lymphocytosis persisted. Sirolimus and tacrolimus failed to maintain normal haemoglobin levels.

In conclusion, we report a rare case of APS1 caused by AIRE mutations presented with PRCA and LGLL. With further literature review, AIRE is thought to be causally related to the development of LGLL and consequent

![Clinical course](image-url)
PRCA due to some immunological mechanisms which need further investigation.

Abbreviations
PRCA: Pure red cell aplasia; LGLL: Large granular lymphocytic leukaemia; APS1: Autoimmune polyendocrine syndrome type 1; AIRE: Autoimmune regulator; WBC: White blood cell; GAD-Ab: Glutamic acid decarboxylase antibody; ASXL1: Additional sex comb like 1, transcriptional regulator; CsA: Cyclosporine A; TCR: T cell receptor.

Acknowledgements
We thank the patient for her cooperation and helpful comments that contributed to this discovery.

Authors’ contributions
MC designed the research study and performed the clinical follow-up. JR collected the medical data. MC and JR were major contributors to the writing of the manuscript. XW and XY J helped with the data analysis and figures. All authors read and approved the final manuscript.

Funding
The work was supported by the National Natural Science Foundation of China (NSFC) (81970106) only for genome sequencing. The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets generated and/or analysed during the current study are available in the NCBI BioProject database under the accession number PRJNA674510.

Ethics approval and consent to participate
Written informed consent to participate was obtained from all of the participants in the study. A copy of the written consent is available for review by the Editor of this journal.

Competing interests
The authors declare that they have no conflicts of interest.

Received: 1 December 2020   Accepted: 29 December 2020
Published online: 19 January 2021

References
1. Means RT Jr. Pure red cell aplasia. Blood. 2016;128(21):2504–9.
2. Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, Teramura M, Karasawa M, Arai A, Yonemura Y, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica. 2008;93(10):1555–9.
3. Husebye ES, Anderson MS, Kampe O. Autoimmune polyendocrine syndromes. N Engl J Med. 2018;378(12):1132–41.
4. Cutolo M. Autoimmune polyendocrine syndromes. Autoimmun Rev. 2014;13(2):85–9.
5. Guo CJ, Leung PSC, Zhang W, Ma X, Gershwin ME. The immunobiology and clinical features of type 1 autoimmune polyglandular syndrome (APS-1). Autoimmun Rev. 2018;17(1):78–85.
6. Bruserud O, Offedal BE, Wolff AB, Husebye ES. AIRE-mutations and autoimmune disease. Curr Opin Immunol. 2016;43:8–15.
7. Malchow S, Leventhal DS, Lee V, Nishi S, Socci ND, Savage PA. Aire enforces immune tolerance by directing autoreactive T cells into the regulatory T cell lineage. Immunity. 2016;44(5):1102–13.
8. Orlowa EM, Sozaeva LS, Kareva MA, Offedal BE, Husebye ES. Expanding the phenotypic and genotypic landscape of autoimmune polyendocrine syndrome type 1. J Clin Endocrinol Metab. 2017;102(9):3546.
9. Gentile M, Verta M, Vigna E, Lucia E, Mazzone C, Perugini D, Gentile C, Bisconte MG, Romeo F, Lleo F, et al. Autoimmune hemolytic anaemia concomitant with sequential autoimmune hepatitis-primary biliary cirrhosis overlap syndrome and Hashimoto’s thyroiditis: a new entity of autoimmune polyendocrine syndrome. J Endocrinol Invest. 2009;32(3):287–8.
10. Satake N, Nakashiki M, Okano M, Tomizawa K, Ishizaka A, Kojima K, Onodera M, Ariga T, Satake A, Sakiyama Y, et al. A Japanese family of X-linked auto-immune enteropathy with haemolytic anaemia and polyendocrinopathy. Eur J Pediatr. 1993;152(4):313–5.
11. Grossi A, Nozzoli C, Gheri R, Santini V, Ferrini PR. Pure red cell aplasia in autoimmune polyglandular syndrome with T lymphocytosis. Haematologica. 1998;83(11):1043–5.
12. Orlowa EM, Kareva MA, Melikyan MA, Boyakov E, Peterkova VA, Maschjan AA. Response of pure red cell aplasia to cyclophosphamide after failure of mycophenolate mofetil in a patient with polyglandular syndrome type I. J Pediatr Hematol Oncol. 2013;35(8):e338-340.
13. Bakrac M, Jurisic V, Kostic T, Popovic V, Pecik S, Krugalic J, Colovic M. Pure red cell aplasia associated with type I autoimmune polyglandular syndrome-successful response to treatment with mycophenolate mofetil: case report and review of literature. J Clin Pathol. 2007;60(6):717–20.
14. Hara T, Mizuno Y, Nagata M, Okabe T, Yashiguchi S, Harada M, Niho Y, Oshimi K, Ohga S, Yoshiki Y, et al. Human gamma delta T-cell receptor-positive cell-mediated inhibition of erythropoiesis in vitro in a patient with type I autoimmune polyglandular syndrome and pure red blood cell aplasia. Blood. 1990;75(4):941–50.
15. Dhodapkar MV, Lust JA, Phyllyk RL. T-cell large granular lymphocytic leukemia and pure red cell aplasia in a patient with type I autoimmune polyendocrinopathy: response to immunosuppressive therapy. Mayo Clin Proc. 1994;69(11):1085–8.
16. Hervier B, Rimbert M, Maisonneuve H, Hamidou MA. Large granular lymphocyte leukemia with pure red cell aplasia associated with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: an unfortuitous association? Int J Immunopathol Pharmacol. 2010;23(3):947–9.
17. Harrison JS, Parnam H, Wang XD. Large granular lymphocytic leukemia complicating autoimmune polyglandular syndrome type 1 in siblings. Clin Case Rep. 2018;6(5):847–50.
18. Drigner N, Bismuth J, Cizeron-Clairac G, Bifren MG, Berthaut C, Serra A, Nottin R, Klattzman D, Cumano A, Barkats M, et al. Estrogen-mediated downregulation of AIRE influences sexual dimorphism in autoimmune diseases. J Clin Investig. 2016;126(4):1525–37.
19. Qiu ZY, Qin R, Tian GY, Wang Y, Zhang YQ. Pathophysiological mechanisms and management of large granular lymphocytic leukemia associated pure red cell aplasia. Onco Targets Ther. 2019;2019(12):8229–40.
20. Qiu ZY, Fan L, Wang L, et al. STAT3 mutations are frequent in T-cell large granular lymphocytic leukemia and pure red cell aplasia. J Hematol Oncol. 2013;6(8):82.
21. Handegretinger R, et al. Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med. 1999;340(4):278–84.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.